Chances are you already know us
Over the years, since our foundation in Japan in 1950, we have built a strong tradition of innovating, developing, manufacturing and marketing high-quality in vitro diagnostics testing solutions worldwide.
The acquisition of Centocor Diagnostics, CanAg Diagnostics and Innogenetics have further bolstered our capabilities and expertise in various clinical areas.
Today, working closely with one of the world’s top commercial laboratories (SRL, Inc.), another entity within the H.U. Group, Fujirebio combines expertise and experience for the diagnostics market that is more potent than ever.
Product categories:
Products by diseases and disorders:
Healthcare for You.
With our deep involvement in human health, we aim to be a group that contributes to the development of healthcare through trust and innovation.
Insight articles
Fujirebio introduces its Neuro Expert Toolbox (NExT) at AAIC 2025
Fujirebio is introducing its Neuro Expert Toolbox (NExT) for the first time at AAIC 2025 (Alzheimer's Association International Conference®) in...
EUROGIN 2025 – key takeaway messages
The EUROGIN 2025 conference, held at the Alfândega Congress Center in Porto, Portugal, focused on advancing scientific efforts to control HPV-related...
Updated anal cancer screening guidelines now provide a basis for expansion of screening to all at-risk populations
Screening guidelines for anal cancer prevention have traditionally focused on people with HIV, and focus on the detection of high-grade squamous...
Video - Alzheimer's awareness redefined
Follow the journey of the Sullivan family and leading Alzheimer’s Neurologist and Researcher Dr. David Greeley as they introduce and explain these...
EUROGIN 2024 – key takeaway messages
The annual EUROGIN conference covers a dense scientific program on the topic of Human papillomavirus (HPV) and its associated cancers, always with a...
Scientific poster – Inter- and intra-laboratory reproducibility of the AmpFire® HPV Screening 16/18/HR assay
This poster summarizes the investigation of the reproducibility (within a laboratory and between laboratories) of the AmpFire HPV Screening 16/18/HR...
